Celebrex-mas: Pfizer Gets Early Present With Juvenile RA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will have to conduct a long-term registry to further evaluate safety concerns with the COX-2 inhibitor, including cardiovascular events.